Lv2
110 积分 2024-03-06 加入
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
2天前
已完结
Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study
2天前
已完结
Finotonlimab with chemotherapy in recurrent or metastatic head and neck cancer: a randomized phase 3 trial
2个月前
已完结
Global burden of oropharyngeal cancer attributable to human papillomavirus by anatomical subsite and geographic region
3个月前
已完结
Cancer incidence and mortality in China, 2022
3个月前
已完结
Safety and preliminary efficacy of puxitatug samrotecan (AZD8205) in patients with endometrial cancer: A first-in-human phase I/IIa study
7个月前
已完结
贝伐珠单抗生物仿制药 IBI305 批准后生产细胞系变更的可比性战略和论证
9个月前
已完结
药物制剂安全性评价及常见问题分析
9个月前
已完结
我国2019年至2021年审评建议批准上市创新药的审评和临床试验现场核查情况分析
10个月前
已完结
监管科学视角下基于风险启动药品注册临床试验现场核查的新思考
10个月前
已完结
皖公网安备34019202002308
